<DOC>
	<DOCNO>NCT02097524</DOCNO>
	<brief_summary>The main purpose study describe pharmacodynamic effect , safety pharmacokinetics single dose sarilumab .</brief_summary>
	<brief_title>Single-dose Study Describe Pharmacodynamics ( PD ) Safety Sarilumab ( REGN88/SAR153191 ) Tocilizumab Adults With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . Patients RA define 2010 revised American College Rheumatology ( ACR ) 2 . ACR Class IIII functional status , base 1991 revise criterion 3 . Treated minimum 12 week Methotrexate stable dose MTX least 8 week prior screen visit 1 . Patients le 18 year age minimum legal age 2 . Prior treatment biologic antiInterleukin 6 ( IL6 ) IL6 Receptor ( IL6R ) antagonists 3 . Use parenteral corticosteroid intraarticular corticosteroid within 4 week prior screen 4 . Use oral corticosteroid dose high prednisone 10 mg equivalent per day , change dosage within 4 week prior randomization 5 . Participation clinical research study evaluate investigational drug therapy within 5 halflives 60 day screen visit , whichever longer 6 . Treatment oral/ biologic DMARDs ( diseasemodifying antirheumatic drug ) , MTX , within certain amount time prior screen visit 7 . Active suspect TB high risk contract TB 8 . Fever , chronic , persistent , recur infection require active treatment 9 . HIV positive Note : The information intend contain consideration relevant patient 's potential participation clinical trial therefore inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>